Kailera Therapeutics completes $718.8M IPO at $16/share with full overallotment exercised

Filed April 20, 2026 · Period ending April 20, 2026 · ~1 min read

Key Changes

• high

  Company raised $718.8 million gross proceeds by selling 44.9 million shares at $16 per share, with underwriters exercising full overallotment option indicating strong investor demand.

  Item 8.01: IPO Completion verify on EDGAR →
• high

  Authorized 800 million common shares and 10 million preferred shares, establishing maximum issuable shares without additional stockholder approval.

  Item 5.03: Certificate Amendment verify on EDGAR →
• medium

  Adopted classified board with three-year staggered terms, requiring two-thirds supermajority vote to remove directors for cause only—standard anti-takeover provisions limiting stockholder control.

  Item 5.03: Governance Changes verify on EDGAR →